Compare TUSK & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TUSK | MNOV |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 137.8M |
| IPO Year | 2016 | 2004 |
| Metric | TUSK | MNOV |
|---|---|---|
| Price | $2.83 | $1.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 73.9K | ★ 792.7K |
| Earning Date | 10-30-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 102.32 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $44,292,000.00 | $2,360,807.00 |
| Revenue This Year | N/A | $78.20 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.56 | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $1.72 | $1.17 |
| 52 Week High | $3.92 | $3.90 |
| Indicator | TUSK | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 40.69 |
| Support Level | $2.80 | $1.28 |
| Resistance Level | $2.94 | $3.90 |
| Average True Range (ATR) | 0.11 | 0.37 |
| MACD | -0.03 | -0.14 |
| Stochastic Oscillator | 7.07 | 1.56 |
Mammoth Energy Services Inc is an integrated energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. The company had three reportable segments, which includes rental services, infrastructure services, natural sand proppant services, accommodation services, and drilling services.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.